NBIX
Neurocrine BiosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The upside case is that Neurocrine sustains commercial execution while the broader program mix begins to convert into durable long-dated growth; the packet's median analyst target of 176.64 still implies modest upside versus the 156.39 anchor.
Posture
Constructive
Lead driver
Momentum
What changed
9 setup hits (3d) with net bullish as of 2026-06-02.
What can break
If commercial momentum and execution are merely in line, the current valuation may already discount a good portion of the constructive tape.
Momentum
88
Value
62
Sentiment
61
Setup hits (3d)
9 · Net Bullish
AI TargetsBase $177.00 · Bull $208.00 · Bear $129.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $176.64
Why
Momentum88 · Δ7d +2.6
Value62 · Δ7d +0.1
Sentiment61 · Δ7d +1.3
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
88
34% active weight
Current posture
7d trendFlat
Δ7d
+2.6
Δ21d
+26.1
Value
62
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
61
33% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
-2.8
Why this grade
Composite grade A. Momentum 87.5 / Value 61.8 / Sentiment 60.6
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$16.19B
Beta
0.31
Shares Out
99.71M
P/E (TTM)
32.5
P/S (TTM)
5.05
P/FCF (TTM)
22.86
Rev YoY
+27.8%
EPS YoY
+64.2%
Gross Margin
+98.4%
Op Margin
+20.5%
Net Debt
-$1.08B
Current Ratio
3.38
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology